Maxim Upgrades Gilead Sciences to Buy, Sees 25% Upside

Maxim analyst Michael Okunewitch upgraded Gilead Sciences (NASDAQ: GILD) from Hold to Buy on May 20, assigning a price target of $165. The new target suggests an upside of over 25% from the stock's current trading level. This upgrade reflects a bullish shift in sentiment from the analyst, who had previously maintained a neutral stance on the biopharmaceutical giant. The $165 target is based on a sum-of-the-parts valuation that accounts for Gilead's core HIV and oncology franchises, as well as its pipeline of experimental therapies.

Gilead Sciences is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs across the US, Europe, and internationally. The upgrade comes as the analyst expects Gilead's core business growth to reach 5%-6%, exceeding previous estimates. This growth is driven by strong sales of its HIV treatments like Biktarvy and the recent launch of its cancer cell therapy Yescarta. With an annual dividend yield of 2.50%, GILD is also recognized among top dividend stocks favored by hedge funds, offering a steady income stream in addition to potential capital appreciation. For traders tracking biotech and pharma moves, NowPrice's real-time commodities dashboard provides live price data on GILD and other key equities, helping investors make informed decisions.

Investors will watch for upcoming earnings reports and pipeline developments to validate the growth outlook. Key catalysts include data readouts from Gilead's experimental drugs in hepatitis B and inflammatory diseases, as well as updates on its Trodelvy breast cancer therapy. The $165 target implies confidence in Gilead's ability to sustain above-trend growth, but market conditions and competitive dynamics remain key factors to monitor. Rival companies like AbbVie and Merck are also vying for market share in HIV and oncology, which could pressure Gilead's pricing power. Additionally, regulatory decisions on new drug approvals and patent expirations on existing products will be critical to watch in the coming quarters.